Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10595505 | Bioorganic & Medicinal Chemistry Letters | 2013 | 8 Pages |
Abstract
Phosphatidylinositol-3-kinase α (PI3Kα) is a therapeutic target of high interest in anticancer drug research. On the basis of a binding model rationalizing the high selectivity and potency of a particular series of 2-aminothiazole compounds in inhibiting PI3Kα, a medicinal chemistry program has led to the discovery of the clinical candidate NVP-BYL719.
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Pascal Furet, Vito Guagnano, Robin A. Fairhurst, Patricia Imbach-Weese, Ian Bruce, Mark Knapp, Christine Fritsch, Francesca Blasco, Joachim Blanz, Reiner Aichholz, Jacques Hamon, Doriano Fabbro, Giorgio Caravatti,